The core problem the researchers set out to solve is one that plagues much of modern pharmacology: getting enough drug to the diseased tissue without poisoning the rest of the body. Pirfenidone is one of only two antifibrotic agents approved for pulmonary fibrosis, yet its clinical benefit is limited by poor accumulation at the sites of active scarring and by systemic side effects that arise when the drug circulates throughout the body after oral or intravenous administration. Patients may tolerate the treatment poorly, and the lesions themselves receive only a fraction of the administered dose.

The team’s solution combines two ideas that have each attracted intense interest in recent years. The first is the exosome, a nanoscale vesicle naturally released by cells to shuttle proteins, lipids, and genetic material between them. Because exosomes are biological in origin, they are relatively invisible to the immune system and can cross biological barriers that defeat synthetic nanoparticles. The researchers harvested exosomes from 293T cells, a standard laboratory cell line, and verified their identity and quality using transmission electron microscopy to visualize their cup-shaped morphology, nanoparticle tracking analysis to measure their size distribution and concentration, Western blotting to confirm the presence of characteristic exosomal marker proteins, and high-performance liquid chromatography to quantify how much pirfenidone each vesicle had been loaded with.

The second idea is molecular targeting. Fibrotic lung tissue is distinguished by the activity of fibroblast activation protein, or FAP, a molecule displayed on the surface of the activated fibroblasts that drive scarring but largely absent from healthy tissue. Using copper-free click chemistry, a bioorthogonal reaction that joins molecules together efficiently under gentle physiological conditions, the team decorated the surface of the exosomes with anti-FAP antibodies. The result is a drug-loaded vesicle that behaves like a guided missile: once in the bloodstream or the airways, it seeks out cells bearing FAP and docks onto them, concentrating its therapeutic payload precisely where the fibrotic process is most active.

How the payload gets to the lung proved to be just as important as the vesicle carrying it. The researchers compared two routes of administration in a bleomycin-induced mouse model of pulmonary fibrosis, a widely used experimental system in which a single dose of the chemotherapy drug bleomycin triggers progressive lung scarring that mimics the human disease. One group of mice received the engineered exosomes by tail vein injection, the standard route for systemic drug delivery. Another group inhaled the same vesicles as an aerosol generated by a nebulizer, a device that converts liquid formulations into fine droplets that can be breathed deep into the lungs.

The difference was striking. In vivo fluorescence imaging, which tracks where labeled vesicles travel in a living animal, showed that nebulization dramatically enhanced both the accumulation of the engineered exosomes in the lungs and the length of time they remained there, compared with systemic injection. Confocal microscopy of lung tissue sections confirmed the same pattern at the cellular level. When the researchers assessed therapeutic outcomes, the nebulized formulation produced better lung histopathology, meaning less architectural distortion of the tissue, and reduced collagen deposition, the hallmark protein accumulation that stiffens fibrotic lungs. The inhaled route also produced stronger suppression of the TGF-β1/p-Smad3 signaling axis, a central molecular pathway through which the cytokine TGF-β1 drives fibroblasts to become collagen-secreting myofibroblasts. Because this pathway sits at the heart of the fibrotic cascade, its more complete inhibition is a meaningful mechanistic win.

But the study went beyond drug delivery and probed how the treatment reshapes the fibrotic microenvironment itself. Using single-cell RNA sequencing, a technique that profiles gene expression in individual cells within a tissue, the researchers found that nebulized delivery of the engineered exosomes attenuated the activation of fibroblasts and myofibroblasts, the cellular engines of scarring. At the same time, the treatment promoted polarization of immune cells toward a repair-associated state, shifting the balance of the lung’s cellular ecosystem from one that perpetuates injury toward one that promotes healing. Proteomic analysis of the tissue, combined with immunofluorescence staining to localize specific proteins, identified AXL, a receptor tyrosine kinase, as a candidate regulatory molecule associated with these beneficial effects.

To test whether AXL was genuinely involved rather than merely correlated, the team turned to cell-based functional experiments. In MLE12 cells, a mouse lung epithelial cell line, and in bone marrow-derived macrophages driven to polarize toward pro-fibrotic phenotypes, the researchers demonstrated that modulating AXL influenced the cellular behaviors that fuel fibrosis. Manipulating the receptor affected pro-fibrotic cellular functions, altered TGF-β1/p-Smad3 signaling, and changed the levels of oxidative stress, a form of cellular damage that both accompanies and promotes fibrotic remodeling. These findings position AXL-associated signaling as a potential mechanistic node in the fibrotic microenvironment and, intriguingly, as a therapeutic target in its own right, suggesting that the exosome platform may work partly by engaging endogenous repair pathways rather than simply delivering a passive drug cargo.

The implications of the study extend in several directions at once. Clinically, an inhaled, targeted formulation of pirfenidone could allow lower doses to achieve greater effect at the lesion while sparing patients the systemic exposure responsible for many side effects, a meaningful prospect for a disease whose treatments are often poorly tolerated. Technologically, the work demonstrates a practical pipeline for engineering exosomes with disease-specific ligands via click chemistry, loading them with small-molecule drugs, and administering them noninvasively through the airways. Scientifically, the identification of AXL as a regulator of the fibrotic microenvironment adds a new thread to the growing understanding of pulmonary fibrosis as a disease of cellular ecology rather than simple scar accumulation. The authors note that their findings establish nebulized anti-FAP-engineered exosomes as a promising targeted delivery platform and highlight microenvironment-focused intervention as a strategy worth pursuing. As with any preclinical mouse study, translation to human patients will require further validation, dose optimization, and safety testing, but the combination of a proven drug, a homing mechanism aimed at a validated disease marker, and a patient-friendly inhalation route gives this platform an unusually clear path toward clinical evaluation.

Subject of Research: Targeted nebulized exosome delivery of pirfenidone for pulmonary fibrosis therapy

Article Title: Mechanisms of nebulized anti-FAP-engineered exosomes encapsulating pirfenidone for targeted therapy of pulmonary fibrosis

Article References: Chen, H., Zhang, G., Kang, C., Liu, H., Tian, W., & Peng, P. (2026). Mechanisms of nebulized anti-FAP-engineered exosomes encapsulating pirfenidone for targeted therapy of pulmonary fibrosis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08894-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08894-5

Keywords: pulmonary fibrosis, exosomes, pirfenidone, nebulization, drug delivery, fibroblast activation protein, TGF-beta signaling, AXL, single-cell RNA sequencing, myofibroblasts, targeted therapy, nanomedicine